Dyslipidemia and lower extremity arterial disease

被引：0

作者：

Paraskevas, Kosmas I. ^{[1
]}

Poredos, Pavel ^{[2
]}

Stanek, Agata ^{[3
,4
]}

Blinc, Ales ^{[2
,5
]}

Jawien, Arkadiusz ^{[6
]}

Antignani, Pier Luigi ^{[7
]}

Mansilha, Armando ^{[8
]}

Mikhailidis, Dimitri P. ^{[9
,10
]}

机构：

[1] Red Cross Hosp, Dept Vasc Surg, 24 Alex Papagou St, Athens 14122, Greece

[2] Univ Med Ctr Ljubljana, Dept Vasc Dis, Ljubljana, Slovenia

[3] Med Univ Silesia, Fac Med Sci Zabrze, Dept Internal Med Angiol & Phys Med, Bytom, Poland

[4] Med Univ Silesia, Clin Internal Med Angiol & Phys Med, Fac Med Sci Zabrze, Bytom, Poland

[5] Univ Ljubljana, Fac Med, Dept Internal Med, Ljubljana, Slovenia

[6] Nicolaus Copernicus Univ Torun, Dept Vasc Surg & Angiol, L Rydygier Coll Med Bydgoszcz, Torun, Poland

[7] Nuova Villa Claudia, Vasc Ctr, Rome, Italy

[8] Univ Porto, Hosp S Joao, Dept Angiol & Vasc Surg, Porto, Portugal

[9] Univ Coll London UCL, Univ Coll London Med Sch, Dept Surg Biotechnol, Div Surg & Intervent Sci, London, England

[10] Univ Coll London UCL, Royal Free Hosp Campus, Dept Clin Biochem, London, England

来源：

INTERNATIONAL ANGIOLOGY | 2024年 / 43卷 / 04期

关键词：

Dyslipidemia; Peripheral arterial disease; Lower extremity arterial disease; Statins; Surgical amputation; AMPUTATION-FREE SURVIVAL; CRITICAL LIMB ISCHEMIA; STATIN THERAPY; LIPID MANAGEMENT; RISK-FACTORS; MORTALITY; CHOLESTEROL; OUTCOMES; ASSOCIATION; LIPOPROTEIN;

D O I：

10.23736/S0392-9590.24.05266-0

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Introduction: Dyslipidemia is an established risk factor for cardiovascular diseases. We aimed to review its role in the pathogenesis of lower extremity arterial disease (LEAD), as well as the effect of lipid-lowering treatment on the progression of LEAD. Evidence acquisition: PubMed/MedLine, EMBASE and Scopus were searched between January 1990 and January 2024 for articles investigating the role of dyslipidemias and hyperlipidemias in the pathogenesis of LEAD. A separate search focused on the effects of lipid-lowering therapy on patients with LEAD. Evidence synthesis: There is evidence that dyslipidemias play a major role in the development of LEAD. All patients with LEAD should receive intensive lipid-lowering therapy for the reduction not only of claudication symptoms and amputation rates, but also of myocardial infarction and cardiovascular event rates. Conclusions: Vascular specialists should keep in mind the pivotal role of dyslipidemia in the pathogenesis and progression of LEAD.

引用

页码：450 / 457

页数：8

共 43 条

[1]

Aday AW, 2018, CIRCULATION, V138, P2330, DOI [10.1161/CIRCULATIONAHA.118.035432, 10.1161/CIRCULATIONAHA.118.034645]

[2] Global epidemiology of lower extremity artery disease in the 21st century (2000-21): a systematic review and meta-analysis [J].

Adou, Caroline ;

Magne, Julien ;

Gazere, Nana ;

Aouida, Maissa ;

Chastaingt, Lucie ;

Aboyans, Victor .

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 31 (07) :803-811

[3] Statins and peripheral arterial disease: Potential mechanisms and clinical benefits [J].

Alnaeb, Mohamad E. ;

Alobaid, Nasser ;

Seifalian, Alexander M. ;

Mikhailidis, Dimitri P. ;

Hamilton, George .

ANNALS OF VASCULAR SURGERY, 2006, 20 (05) :696-705

[4] Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease [J].

Arya, Shipra ;

Khakharia, Anjali ;

Binney, Zachary O. ;

DeMartino, Randall R. ;

Brewster, Luke P. ;

Goodney, Philip P. ;

Wilson, Peter W. F. .

CIRCULATION, 2018, 137 (14) :1435-1446

[5] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].

Baigent, C. ;

Blackwell, L. ;

Emberson, J. ;

Holland, L. E. ;

Reith, C. ;

Bhala, N. ;

Peto, R. ;

Barnes, E. H. ;

Keech, A. ;

Simes, J. ;

Collins, R. .

LANCET, 2010, 376 (9753) :1670-1681

[6] Statin Intolerance Some Practical Hints [J].

Banach, Maciej ;

Mikhailidis, Dimitri P. .

CARDIOLOGY CLINICS, 2018, 36 (02) :225-231

[7] Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel [J].

Banach, Maciej ;

Rizzo, Manfredi ;

Toth, Peter P. ;

Farnier, Michel ;

Davidson, Michael H. ;

Al-Rasadi, Khalid ;

Aronow, Wilbert S. ;

Athyros, Vasilis ;

Djuric, Dragan M. ;

Ezhov, Marat V. ;

Greenfield, Robert S. ;

Hovingh, G. Kees ;

Kostner, Karam ;

Serban, Corina ;

Lighezan, Daniel ;

Fras, Zlatko ;

Moriarty, Patrick M. ;

Muntner, Paul ;

Goudev, Assen ;

Ceska, Richard ;

Nicholls, Stephen J. ;

Broncel, Marlena ;

Nikolic, Dragana ;

Pella, Daniel ;

Puri, Raman ;

Rysz, Jacek ;

Wong, Nathan D. ;

Bajnok, Laszlo ;

Jones, Steven R. ;

Ray, Kausik K. ;

Mikhailidis, Dimitri P. .

ARCHIVES OF MEDICAL SCIENCE, 2015, 11 (01) :1-23

[8] Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) [J].

Bonaca, Marc P. ;

Nault, Patrice ;

Giugliano, Robert P. ;

Keech, Anthony C. ;

Pineda, Armando Lira ;

Kanevsky, Estella ;

Kuder, Julia ;

Murphy, Sabina A. ;

Jukema, J. Wouter ;

Lewis, Basil S. ;

Tokgozoglu, Lale ;

Somaratne, Ransi ;

Sever, Peter S. ;

Pedersen, Terje R. ;

Sabatine, Marc S. .

CIRCULATION, 2018, 137 (04) :338-350

[9] Prevalence of statin intolerance: a meta-analysis [J].

Bytyci, Ibadete ;

Penson, Peter E. ;

Mikhailidis, Dimitri P. ;

Wong, Nathan D. ;

Hernandez, Adrian, V ;

Sahebkar, Amirhossein ;

Thompson, Paul D. ;

Mazidi, Mohsen ;

Rysz, Jacek ;

Pella, Daniel ;

Reiner, Zeljko ;

Toth, Peter P. ;

Banach, Maciej .

EUROPEAN HEART JOURNAL, 2022, 43 (34) :3213-3223

[10] Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease [J].

Cheng, SWK ;

Ting, ACW ;

Wong, J .

EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 1997, 14 (01) :17-23

← 1 2 3 4 5 →